Interferon regulatory factor-1 gene abnormality and loss of growth inhibitory effect of interferon-α in human hepatoma cell lines

International Journal of Oncology

Volumn 13, Issue 6, 1998, Pages 1207-1216

  Tada, Shinichiro ^a   Saito, Hidetsugu ^a   Tsunematsu, Satoshi ^a   Ebinuma, Hirotoshi ^a   Wakabayashi, Kanji ^a   Masuda, Tetsuya ^a   Ishii, Hiromasa ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Chronic hepatitis C; Hepatocellular carcinoma; Interferon; Interferon regulatory factor 1

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON RECEPTOR; BETA INTERFERON; INTERFERON REGULATORY FACTOR 1; PROTEIN P21;

ARTICLE; CANCER GROWTH; CHRONIC HEPATITIS; CONTROLLED STUDY; HEPATITIS C; HEPATOMA CELL; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; INTERFERON PRODUCTION; POINT MUTATION; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

BASE SEQUENCE; BLOTTING, SOUTHERN; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL DIVISION; DNA, NEOPLASM; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTOR-1; INTERFERON REGULATORY FACTOR-2; INTERFERON-ALPHA; MOLECULAR SEQUENCE DATA; PHOSPHOPROTEINS; POINT MUTATION; RECEPTORS, INTERFERON; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SEQUENCE ALIGNMENT; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0031772069     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, Shiomi S, Seki S, Kobayashi K and Otani S: Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 346: 1051-1055, 1995.
2. Benvegn L and Alberti A: Risk factors and prevention of hepatocellular carcinoma in HCV infection. Dig Dis Sci 41: 49S-55S, 1996.
3. Kuwana K, Ichida T, Kamimura T, Ohkoshi S, Ogata N, Harada T, Endoh K and Asakura H: Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients. J Gastroenterol Hepatol 12: 149-155, 1997.
4. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, Novelli V, Cipolla A, Fabbri C, Pezzoli A and Roda E: Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 24: 141-147, 1996.
5. International Interheron-alpha Hepatocellular Carcinoma Study Group: Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 351: 1394-1402, 1998.
6. Terada M, Ikegami F, Baba T, Oota M, Ooyama T, Sezai S, Ito M, Sakurai Y, Kamisaka K, Abe T and Tanaka Y: Incidence of hepatocellular carcinoma (HCC) in chronic hepatitis C patients treated with interferon (IFN). Acta Hepatol Jpn 38: 355-360, 1997.
7. Testa U, Ferbus D, Gabbianelli M, Pascucci B, Boccoli G, Louache F and Thang MN: Effect of endogenous and exogenous interferons on the differentiation of human monocyte cell line U937. Cancer Res 48: 82-88, 1988.
8. Marth C, Zeimet AG, Herold M, Brumm C, Windbichler G, Muler-Holzner E, Offner F, Feichtinger H, Zwierzina H and Daxenbichler G: Different effects of interferons, interleukin-1 beta and tumor necrosis factor-alpha in normal (OSE) and malignant human ovarian epithelial cells. Int J Cancer 67: 826-830, 1996.
9. Tiefenbrun N and Kimchi A: The involvement of protein kinase C in mediating growth suppressive signals of interferons in hematopoietic cells. Oncogene 6: 1001-1007, 1991.
10. Von Wussow P, Pralle H, Hochkeppel H-K, Jakschies D, Sonnen S, Schmidt H, Müller-Rosenau D, Franke M, Haferiach T, Zwingers T, Rapp U and Deicher H: Effective natural interferon-α therapy in recombinant interferon-α-resistant patients with hairy cell leukemia. Blood 78: 38-43, 1991.
11. Sugiura N, Sakai Y, Ebara M, Fukuda H, Yoshikawa M, Saisho H, Ohto M and Kondo F: Detection of hepatocellular carcinoma after interferon therapy for chronic hepatitis C. J Gastroenterol Hepatol 6: 535-539, 1996.
12. Tamori A, Kuroki T, Nishiguchi S, Morimoto H, Morimoto M, Hirohashi K, Kinoshita AH and Kobayashi K: Case of small hepatocellular carcinoma in the caudate lobe detected after interferon caused disappearance of hepatitis C virus. Hepatogastroenterology 43: 1079-1083, 1996.
13. Maruyama M, Fujita T and Taniguchi T: Sequence of a cDNA coding for human IRF-1. Nucleic Acids Res 17: 3292, 1989.
14. Tanaka N, Ishihara M and Taniguchi T: Suppression of c-myc or fosB-induced cell transformation by the transcription factor IRF-1. Cancer Lett 83: 191-196, 1994.
15. Harada H, Takahashi E, Itoh S, Harada K, Hod TA and Taniguchi T: Structure and regulation of the human interferon regulatory factor 1 (IRF-1) and IRF-2 genes: implications for a gene network in the interferon system. Mol Cell Biol 14: 1500-1509, 1994.
16. Taniguchi T, Harada H and Lamphier M: Regulation of the interferon system and cell growth by the IRF transcription factors. J Cancer Res Clin Oncol 121: 516-520, 1995.
17. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC, List AF and Taniguchi T: Deletion of IRF-1 mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 259: 968-971, 1993.
18. Harada H, Kondo T, Ogawa S, Tamura T, Kitagawa M, Tanaka N, Lamphier MS, Hirai H and Taniguchi T: Accelerated exon skipping of IRF-1 mRNA in human myelodysplasia/leukemia: a possible mechanism of tumor suppressor inactivation. Oncogene 9: 3313-3320, 1994.
19. Nishida N, Fukuda N and Ishizaki K: Molecular aspects of hepatocarcinogenesis and their clinical implications. Int J Oncol 4: 615-622, 1994.
20. Tabor E: Tumor suppressor genes, growth factor genes, and oncogenes in hepatitis B virus-associated hepatocellular carcinoma. J Med Virol 42: 357-365, 1994.
21. Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodes J and Bartrons R: c-met mRNA overexprcssion in human hepatocellular carcinoma. Hepatology 19: 88-91, 1994.
22. Tsunematsu S, Saito H, Kagawa T, Morizane T, Hata J, Nakamura T, Ishii H, Tsuchiya M, Nomura T and Katsuki M: Hepatic tumors induced by carbon tetrachloride in transgenic mice carryine a human c-Ha-ras protooncogenc without mutations. Int J Cancer 59: 554-559, 1994.
23. Fujimoto Y, Hampton LL, Wirth PJ, Wang NJ, Xie JP and Thorgeirsson SS: Alteration of tumor suppressor genes and allulic losses in human hepatocellular carcinomas in China. Cancer Res 54: 281-285, 1994.
24. Saito H, Morizane T, Watanabe T, Kagawa T, Iwabuchi N, Kumagai N, Inagaki Y, Tsuchimoto K and Tsuchiya M: Establishment of a human cell line (HCC-T) from a patient with hepatoma bearing no evidence of hepatitis B or A virus infection. Cancer 64: 1054-1060, 1989.
25. Watanabe T, Morizane T, Tsuchimoto K, Inagaki Y, Munakata Y, Nakamura T, Kumagai N and Tsuchiya M: Establishment of a cell line (HCC-M) from a human hepatocellular carcinoma. Int J Cancer 32: 141-146, 1983.
26. Alexander JJ, Bey EM, Geddes EW and Lecatsas G: Establishment of a continuously growing cell line from primary carcinoma of the liver. S Afr Med J 50: 2124-2128, 1976.
27. Doi I, Namba M and Sato J: Establishment and some biological characteristics of human hepatoma cell lines. Gann 66: 385-392, 1975.
28. Chang RSM: Continuous subcultivation of epithelial-like cells from normal human tissues. Proc Soc Exp Biol Mcd 87: 440-443, 1954.
29. Saito H, Morizane T, Watanabe T, Kagawa T, Miyaguchi S, Kumagai N and Tsuchiya M: Differentiating effect of sodium butyratc on human hepatoma cell lines PLC/PRF/5, HCC-M and HCC-T. Int J Cancer 48: 291-296, 1991.
30. Saito H, Tada S, Ebinuma H, Tsunematsu S, Kagawa T, Kumagai N, Inagaki Y, Watanabe T, Tsuchimoto K, Morizane T, Ishii H and Tsuchiya M: Changes of antigen expression on human hepatoma cell lines caused by sodium butyrate, a differentiation inducer. J Gastroenterol 29: 733-739, 1994.
31. Cory AH, Owen TC, Barltrop JA and Cory JG: Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture. Cancer Commun 3: 207-212, 1991.
32. Roos G, Leanderson T and Lundgren E: Interferon-induced cell cycle changes in human hematopoietic cell lines and fresh leukemia cells. Cancer Res 44: 2358-2362, 1984.
33. Shinomiya N, Shinomiya M, Wakiyama H, Katsura Y and Rokutanda M: Enhancement of CDDP cytotoxicity by caffeine is characterized by apoptotic cell death. Exp Cell Res 210: 236-242, 1994.
34. Jiamg H, Lin J, Su Z-Z, Herlyn M, Kerbel RS, Weissman BE, Welch DR and Fisher PB: The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. Oncogene 10: 1855-1864, 1995.
35. Saito H, Ebinuma H, Takahashi M, Kaneko F, Wakabayashi K, Nakamura M and Ishii H: Loss of butyrate-induced apoptosis in human hepatoma cell lines HCC-M and HCC-T having substantial bcl-2 expression. Hepatology 27: 1233-1240, 1998.
36. Saito H, Morizane T, Watanabe T, Kagawa T, Miyaguchi S, Kumagai N, Tsuchimoto K and Tsuchiya M: Protooncogene expression in three human hepatoma cell lines, HCC-M, HCC-T and PLC/PRF/5. Keio J Med 40: 139-145, 1991.
37. Prasad R, Leshkowitz D, Gu Y, Alder H, Nakamura T, Saito H, Huebner K, Berger R, Croce CM and Canaani E: Leucinezipper dimerization motif encoded by the AF17 gene fused to ALL-1 (MLL) in acute leukemia. Proc Natl Acad Sci USA 91: 8107-8111, 1994.
38. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Persons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor supression. Cell 75: 817-825, 1993.
39. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D: Induction of WAF1/CP1 by p53 independent pathway. Cancer Res 54: 3391-3395, 1994.
40. Hobeika AC, Subramaniam PS and Johnson HM: IFN alpha induces the expression of the cyclin-dependent kinase inhibitor p21 in human prostate cancer cells. Oncogene 14: 1165-1170, 1997.
41. Sangfelt O, Erickson S, Einhorn S and Grander D: Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines. Oncogene 14: 415-413, 1997.
42. Lai CL, Lau JYN, Wu PC, Nghan H, Chung HT, Nitchell SJ, Corbett TJ, Chow AWC and Lin HJ: Recombinant interferon-α in inoperable hepatocellular carcinoma; a randomized controlled trial. Hepatology 17: 389-394, 1993.
43. Kountouras J, Boura A, Karolides A, Zaharioudaki E and Tsapas G: Recombinant a2 interferon with chemohormonal therapy in patients with hepatocellular carcinoma. Hepatosastroenterology 42: 31-36, 1995.
44. Cao XT, Wang JL, Zhang WP, Chen GY, Kong XT and Tani K: Treatment of human hepatocellular carcinoma by fibroblast-mediated human interferon α gene therapy in combination with adoptive chemoimmunotherapy. J Cancer Res Clin Oncol 121: 457-462, 1995.
45. Darnell JE, Kerr I and Stark G: Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264: 1415-1421, 1994.
46. Taniguchi T: Cytokine signaling through non-receptor protein tyrosine kinases. Science 268: 251-255, 1995.
47. Miyamoto M, Fujita T, Kimura Y, Maruyama M, Harada H, Sudou Y, Miyata T and Taniguchi T: Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-B gene regulatory elements. Cell 54: 903-913, 1988.
48. Harada H, Fujita T, Miyamoto M, Kimura Y, Maruyama M, Furia A, Miyata T and Taniguchi T: Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell 58: 729-739, 1989.
49. Kirchhoff S, Schaper F and Hauser H: Interferon regulatory factor 1 (IRF-1) mediates cell growth inhibition by transactivation of downstream target genes. Nucleic Acids Res 21: 2881-2889, 1993.
50. Harada H, Kitagawa M, Tanaka N, Yamamoto H, Harada K, Ishihara M and Taniguchi T: Antioncogenic and oncogenic potentials of interferon regulatory factor-1 and -2. Science 259: 971-974, 1993.
51. Tanaka N, Ishihara M, Lamphier MS, Nozawa H, Matsuyama T, Mak TW, Aizawa S, Tokino T, Oren M and Taniguchi T: Cooperation of the tumor suppressors IRF-1 and p53 in response to DNA damage. Nature 382: 816-818, 1996.
52. Itoh S, Harada H, Nakamura Y, White R and Taniguchi T: Assignment of the human interferon regulatory factor-1 (IRF-1) gene to chromosome 5q23-31. Genomics 10: 1097-1099, 1991.
53. Le Beau MM: Deletions of chromosome 5 in malignant myeloid disorders. Cancer Surv 15: 144-159, 1992.
54. Konishi M, Kikuchi-Yanoshita R, Tanaka K, Sato C, Tsuruta K, Maeda Y, Koike M, Tanaka S, Nakamura Y, Hattori N and Miyaki M: Genetic changes and histopathological grades in human hepatocellular carcinoma. Jpn J Cancer Res 84: 893-899, 1993.
55. Nakao K, Nakata K, Daikoku M, Inokuchi K, Nomura T, Ido A, Tsuruta S, Kato Y, Ishii N and Nagataki S: Analysis of interferon regulatory factor I and 2 gene expression in human hepatoma cell lines. Int Hepatol Commun 4: 351-357, 1996.
56. Saito H, Morizane T, Inagaki Y, Kumagai N, Watanabe T, Nakamura T, Satoh I, Sawaguchi K, Iwabuchi N, Tsuchimoto K and Tsuchiya M: Decrease of transplantability by the immunopotentiators, OK-432 and interleukin-2: experiments on a human hepatoma cell line in nude mice. Eur J Cancer 25: 79-89, 1989.
57. Saito H, Fukumura D, Kurose I, Suematsu M, Tada S, Kagawa T, Miura S, Morizane T and Tsuchiya M: Visualization of oxidative processes at the cellular level during neutrophil-mediated cylotoxicity against a human hepatoma cell line, HCC-M. Int J Cancer 51: 124-129, 1992.
58. Saito H, Kurose I, Ebinuma H, Fukumura D, Higuchi H, Atsukawa K, Tada S, Kimura H, Yonei Y, Masuda T, Miura S and Ishii H: Kupffer cell-mediated cytotoxicity against hepatoma cells occurs through production of nitric oxide and adhesion via ICAM-1/CD18. Int Immunol 8: 1165-1172, 1996.
59. Onitsuka A, Yamada N, Yasuda H, Miyata T and Kachi T: Rapid growth of hepatoccllular carcinoma after or during interferon treatment of chronic hepatitis C: report of three cases. Surg Today 26: 126-130, 1996.
60. Ichida F, Tsuji T, Omata M, Ichida T, Inoue K, Kamimura T, Yamada G, Hino K, ,Yokosuka O and Suzuki H: Classification report New Inuyama classification: new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun 6: 112-119, 1996.